Lortholary, O., Petrikkos, G., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., Cornely, O. A., Cuenca-Estrella, M., Donnelly, J. P., Garbino, J., Groll, A. H., Herbrecht, R., Hope, W. W., Jensen, H. E., Kullberg, B. J., Lass-Floerl, C., Meersseman, W., Richardson, M. D., Roilides, E., Verweij, P. E., Viscoli, C. and Ullmann, A. J. (2012). ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin. Microbiol. Infect., 18. S. 68 - 78. OXFORD: ELSEVIER SCI LTD. ISSN 1469-0691

Full text not available from this repository.

Abstract

Clin Microbiol Infect 2012; 18 (Suppl. 7): 6877 Abstract Mucosal candidiasis is frequent in immunocompromised HIV-infected highly active antiretroviral (HAART) naive patients or those who have failed therapy. Mucosal candidiasis is a marker of progressive immune deficiency. Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre-HAART era. Fluconazole remains the first line of therapy for both oropharyngeal candidiasis and oesophageal candidiasis and should be preferred to itraconazole oral solution (or capsules when not available) due to fewer side effects. For patients who still present with fluconazole-refractory mucosal candidiasis, oral treatment with any other azole should be preferred based on precise Candida species identification and susceptibility testing results in addition to the optimization of HAART when feasible. For vaginal candidiasis, topical therapy is preferred.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Lortholary, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Petrikkos, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Akova, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arendrup, M. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arikan-Akdagli, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bassetti, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bille, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Calandra, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castagnola, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cornely, O. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cuenca-Estrella, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Donnelly, J. P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Garbino, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Groll, A. H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herbrecht, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hope, W. W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jensen, H. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kullberg, B. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lass-Floerl, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meersseman, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Richardson, M. D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roilides, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Verweij, P. E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Viscoli, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ullmann, A. J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-477889
DOI: 10.1111/1469-0691.12042
Journal or Publication Title: Clin. Microbiol. Infect.
Volume: 18
Page Range: S. 68 - 78
Date: 2012
Publisher: ELSEVIER SCI LTD
Place of Publication: OXFORD
ISSN: 1469-0691
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
HUMAN-IMMUNODEFICIENCY-VIRUS; ITRACONAZOLE ORAL SOLUTION; REFRACTORY OROPHARYNGEAL CANDIDIASIS; FLUCONAZOLE-RESISTANT CANDIDA; DOUBLE-BLIND; ESOPHAGEAL CANDIDIASIS; IN-VITRO; CLOTRIMAZOLE TROCHES; MUCOSAL CANDIDIASIS; FUNGAL-INFECTIONSMultiple languages
Infectious Diseases; MicrobiologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/47788

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item